Seres Therapeutics, Inc. (NASDAQ:MCRB) has been assigned a $20.00 price target by equities researchers at Canaccord Genuity in a research note issued on Thursday. The firm currently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity’s target price points to a potential upside of 46.09% from the company’s current price.

MCRB has been the topic of a number of other research reports. Cantor Fitzgerald set a $16.00 price target on shares of Seres Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 4th. ValuEngine upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. BidaskClub upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Friday, July 14th. Finally, Cowen and Company reiterated a “buy” rating on shares of Seres Therapeutics in a research note on Friday, May 19th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Seres Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $16.17.

Shares of Seres Therapeutics (NASDAQ MCRB) traded up 6.04% on Thursday, reaching $13.69. 328,137 shares of the company’s stock were exchanged. Seres Therapeutics has a 12 month low of $8.85 and a 12 month high of $15.09. The firm’s 50-day moving average price is $11.94 and its 200 day moving average price is $10.51. The company’s market cap is $552.94 million.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by $0.10. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 73.45%. The company had revenue of $3 million during the quarter, compared to analyst estimates of $3 million. During the same quarter last year, the company posted ($0.70) EPS. The firm’s quarterly revenue was up .0% on a year-over-year basis. Equities research analysts predict that Seres Therapeutics will post ($2.56) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/06/seres-therapeutics-inc-nasdaqmcrb-pt-set-at-20-00-by-canaccord-genuity.html.

Several hedge funds and other institutional investors have recently made changes to their positions in MCRB. Parametric Portfolio Associates LLC raised its position in shares of Seres Therapeutics by 1.3% in the first quarter. Parametric Portfolio Associates LLC now owns 21,335 shares of the biotechnology company’s stock worth $240,000 after buying an additional 279 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Seres Therapeutics by 0.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 91,543 shares of the biotechnology company’s stock worth $1,035,000 after buying an additional 494 shares during the last quarter. American International Group Inc. raised its position in shares of Seres Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock worth $124,000 after buying an additional 727 shares during the last quarter. Alps Advisors Inc. raised its position in shares of Seres Therapeutics by 5.0% in the second quarter. Alps Advisors Inc. now owns 36,457 shares of the biotechnology company’s stock worth $412,000 after buying an additional 1,739 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of Seres Therapeutics by 14.8% in the second quarter. Rhumbline Advisers now owns 22,472 shares of the biotechnology company’s stock worth $254,000 after buying an additional 2,890 shares during the last quarter. Hedge funds and other institutional investors own 75.52% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.